Patents by Inventor Yaron TOMER

Yaron TOMER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING AND/OR PREVENTING TYPE 1 DIABETES WITH CEPHARANTHINE
    Publication number: 20240342158
    Abstract: This disclosure provides methods of treating and/or preventing type 1 diabetes (T1D) and/or a syndrome including type 1 diabetes and autoimmune thyroiditis in a subject. The methods include administering a therapeutically effective amount of cepharanthine or a pharmaceutically acceptable salt, solvate or derivative thereof to the subject, wherein the subject has a human leucocyte antigen class II, DR3 allele (HLA-DR3) genotype.
    Type: Application
    Filed: August 1, 2022
    Publication date: October 17, 2024
    Inventors: Yaron TOMER, Cheuk Wun LI
  • METHOD FOR PREDICTING PATIENT RESPONSE TO CD40-TARGETED THERAPIES
    Publication number: 20240002941
    Abstract: Methods of predicting response of a subject in need of immunosuppressant therapy to a Cluster of differentiation 40 (CD40)-targeted treatment are disclosed. The methods permit treating the subject with a treatment most likely to show a favorable response.
    Type: Application
    Filed: December 2, 2021
    Publication date: January 4, 2024
    Inventors: Yaron Tomer, Larissa C. Faustino, George J. Kahaly
  • PEPTIDES THAT BLOCK PRESENTATION OF ANTIGENIC ISLET PEPTIDES BY HLA-DQ8 AND METHODS FOR TREATING TYPE-1 DIABETES
    Publication number: 20220306722
    Abstract: The disclosure provides polypeptides that specifically bind to HLA-DQ8 for treating Type 1 Diabetes (TID) and methods using same for reducing autoimmune destruction of pancreatic islet beta cells. In particular, the present disclosure relates to peptides containing at least one D-amino acid that are capable of blocking the presentation of antigenic islet peptides (e.g., lnsB:9-23) by HLA-DQ8, and to their uses, especially as it relates to the prevention and/or treatment of TID.
    Type: Application
    Filed: August 4, 2020
    Publication date: September 29, 2022
    Applicants: Icahn School of Medicine at Mount Sinai, Montefiore Medical Center, Albert Einstein College of Medicine, Inc.
    Inventors: Yaron Tomer, Roman Osman, Angela Lombardi
  • Small molecule inhibitors of HLA-DR3 binding for treating autoimmune thyroiditis
    Patent number: 11266642
    Abstract: A method for treating autoimmune thyroid disease is disclosed. The method comprises administering a molecule of molecular weight below 700 that inhibits the binding of the nonadecapeptide IPDNLFLKSDGRIKYTLNK (SEQ ID NO:1) to HLA-DR?1-Arg74.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: March 8, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Yaron Tomer, Roman Osman
  • SYSTEMS AND METHODS FOR PERSONALIZED RETARGETING
    Publication number: 20200387928
    Abstract: A personalized retargeting method is provided. The personalized retargeting method involves receiving a first data set that includes one or more data items indicating options that are unique to a user for a customized product. A second data set that is similar to the first data set is transmitted to a retargeting platform for display with a banner when the user visits a second website. Once the first data set is validated by the retargeting platform, then the first data set is transmitted to the retargeting platform for display with a banner when the user visits the second website.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 10, 2020
    Applicant: XMPie (Israel) Ltd.
    Inventors: Gilad MADMONI, Yaron Tomer, Amit Cohen
  • SMALL MOLECULE INHIBITORS OF HLA-DR3 BINDING FOR TREATING AUTOIMMUNE THYROIDITIS
    Publication number: 20200281919
    Abstract: A method for treating autoimmune thyroid disease is disclosed. The method comprises administering a molecule of molecular weight below 700 that inhibits the binding of the nonadecapeptide IPDNLFLKSDGRIKYTLNK (SEQ ID NO:1) to HLA-DR?1-Arg74.
    Type: Application
    Filed: December 20, 2016
    Publication date: September 10, 2020
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Yaron TOMER, Roman OSMAN